SRC and brain disorder: The quality markers of GR in the treatment of brain diseases after processing have been preliminarily identified to include gastrodin, S-(4-hydroxybenzyl)-glutathione, and the parishins B, C, and E. These markers may exhibit therapeutic effects against AD, MDD, and CI by acting on the pathways involving AKT1, SRC, MAPK, and other proteins.